Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson recently reported third-quarter adjusted earnings per share of $2.59, which exceeded the consensus estimate of $2.53, while revenue of $25.40 billion rose 5.9% year over year, demonstrating strong fundamental performance that supports the current stock price of $275.17.
• The company presented a record 26 abstracts at the 2026 Transcatheter Cardiovascular Therapeutics conference, adding to more than two decades of data on the safety, efficacy, and cost-effectiveness of its Impella heart pumps, which reinforces the competitive positioning of its MedTech portfolio.
• Johnson & Johnson is seeing rapid uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices, with independent physician research indicating that prescriptions are building momentum and gaining share within the oral advanced therapy segment, potentially delaying the initiation of higher-cost biologic drugs.
• Broader strength among large pharmaceutical companies is helping sector sentiment, with peers like Merck and Eli Lilly posting strong results, which places Johnson & Johnson among several major healthcare names attracting significant investor interest and capital flows.
• The company maintains a stable dividend profile, having recently announced a quarterly dividend of $1.34 per share to be paid on December 8th, representing an annualized yield of approximately 1.9% that provides income stability for investors.